Glenmark Pharmaceuticals on Wednesday received final approval from the USFDA for Arformoterol Tartrate inhalation solution, 15 mcg/2 mL.
Arformoterol Tartrate inhalation solution is generic version of BROVANA inhalation solution of Sunovion Pharmaceuticals Inc. Arformoterol Tartrate inhalation solution unit-dose vials will be manufactured in the company's North American manufacturing facility based in Monroe, North Carolina, and marks the company's first nebulizer approval.
According to IQVIA sales data for the 12 month period ended April 2021, the BROVANA Inhalation Solution market achieved annual sales of approximately $437.9 million.
Commenting on the launch, Sanjeev Krishan, president of Glenmark North America said, We are one of the first generic companies to receive approval. This marks our third approval from our manufacturing facility in Monroe in 2021.
Glenmark's current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Shares of Glenmark Pharmaceuticals were trading 0.46% higher at Rs 643.65 on BSE.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across generics, specialty and over-the-counter (OTC) business with operations in over 50 countries.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU